Brief: OPTIMIZERx Q2 Revenue USD 29.2 Million Vs. IBES Estimate USD 22.3 Million

OptimizeRx

07/08/2025 21:01

Overview

OptimizeRx Q2 revenue grows 55% yr/yr, beating analyst expectations, per LSEG data

Adjusted EBITDA for Q2 beats consensus, reflecting strong operational performance

Co raises full-year 2025 guidance for revenue and adjusted EBITDA

Outlook

Company raises 2025 revenue guidance to $104 mln-$108 mln

OptimizeRx expects 2025 adjusted EBITDA of $14.5 mln-$17.5 mln

Result Drivers

AI TECHNOLOGY - OptimizeRx attributes revenue growth to market-leading patient finding AI technology

DEBT REDUCTION - Co paid down $4.5 mln on term loan, exceeding scheduled payments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$29.20 mln
$22.30 mln (7 Analysts)
Q2 Adjusted Net Income
Beat
$4.50 mln
$206,200 (6 Analysts)
Q2 Adjusted EBITDA
Beat
$5.80 mln
$1.31 mln (7 Analysts)
Q2 Cash & Investments
$16.60 mln
Q2 Gross Profit
$18.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the online services peer group is "buy"

Wall Street's median 12-month price target for OptimizeRx Corp is $16.00, about 22% above its August 6 closing price of $12.48

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nGNX3H2hG7

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)